1072 related articles for article (PubMed ID: 25355891)
1. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
[TBL] [Abstract][Full Text] [Related]
2. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
3. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
Perdiguero B; Sánchez-Corzo C; Sorzano COS; Saiz L; Mediavilla P; Esteban M; Gómez CE
Viruses; 2019 Feb; 11(2):. PubMed ID: 30781504
[TBL] [Abstract][Full Text] [Related]
4. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney J; Seaman M; Montefiori DC; Labranche C; Yates NL; Shen X; Tomaras GD; Ferrari G; Foulds KE; McDermott A; Kao SF; Roederer M; Hawkins N; Self S; Yao J; Farrell P; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo A; Weiss D; Lee C; Kibler K; Jacobs B; Asbach B; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2015 Aug; 89(16):8525-39. PubMed ID: 26041302
[TBL] [Abstract][Full Text] [Related]
5. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.
Asbach B; Kliche A; Köstler J; Perdiguero B; Esteban M; Jacobs BL; Montefiori DC; LaBranche CC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Landucci G; Forthal DN; Seaman MS; Hawkins N; Self SG; Sato A; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Francis J; Galmin L; Ding S; Heeney JL; Pantaleo G; Wagner R
J Virol; 2016 Apr; 90(8):4133-4149. PubMed ID: 26865719
[TBL] [Abstract][Full Text] [Related]
6. Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.
Perdiguero B; Gómez CE; García-Arriaza J; Sánchez-Corzo C; Sorzano CÓS; Wilmschen S; von Laer D; Asbach B; Schmalzl C; Peterhoff D; Ding S; Wagner R; Kimpel J; Levy Y; Pantaleo G; Esteban M
Front Immunol; 2019; 10():2941. PubMed ID: 31921191
[TBL] [Abstract][Full Text] [Related]
7. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.
Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y
J Virol; 2017 May; 91(9):. PubMed ID: 28202751
[TBL] [Abstract][Full Text] [Related]
8. The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses.
Storcksdieck genannt Bonsmann M; Niezold T; Hannaman D; Überla K; Tenbusch M
Vaccine; 2016 Apr; 34(15):1744-51. PubMed ID: 26945099
[TBL] [Abstract][Full Text] [Related]
9. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
10. Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.
Kibler KV; Asbach B; Perdiguero B; García-Arriaza J; Yates NL; Parks R; Stanfield-Oakley S; Ferrari G; Montefiori DC; Tomaras GD; Roederer M; Foulds KE; Forthal DN; Seaman MS; Self S; Gottardo R; Phogat S; Tartaglia J; Barnett S; Cristillo AD; Weiss D; Galmin L; Ding S; Heeney JL; Esteban M; Wagner R; Pantaleo G; Jacobs BL
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429340
[TBL] [Abstract][Full Text] [Related]
11. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.
Harari A; Bart PA; Stöhr W; Tapia G; Garcia M; Medjitna-Rais E; Burnet S; Cellerai C; Erlwein O; Barber T; Moog C; Liljestrom P; Wagner R; Wolf H; Kraehenbuhl JP; Esteban M; Heeney J; Frachette MJ; Tartaglia J; McCormack S; Babiker A; Weber J; Pantaleo G
J Exp Med; 2008 Jan; 205(1):63-77. PubMed ID: 18195071
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
[TBL] [Abstract][Full Text] [Related]
13. Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges.
Khattar SK; Manoharan V; Bhattarai B; LaBranche CC; Montefiori DC; Samal SK
mBio; 2015 Jul; 6(4):e01005. PubMed ID: 26199332
[TBL] [Abstract][Full Text] [Related]
14. Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.
Bridge SH; Sharpe SA; Dennis MJ; Dowall SD; Getty B; Anson DS; Skinner MA; Stewart JP; Blanchard TJ
Virol J; 2011 Sep; 8():429. PubMed ID: 21899739
[TBL] [Abstract][Full Text] [Related]
15. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
Asbach B; Kibler KV; Köstler J; Perdiguero B; Yates NL; Stanfield-Oakley S; Tomaras GD; Kao SF; Foulds KE; Roederer M; Seaman MS; Montefiori DC; Parks R; Ferrari G; Forthal DN; Phogat S; Tartaglia J; Barnett SW; Self SG; Gottardo R; Cristillo AD; Weiss DE; Galmin L; Ding S; Heeney JL; Esteban M; Jacobs BL; Pantaleo G; Wagner R
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429343
[TBL] [Abstract][Full Text] [Related]
16. A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.
Meador LR; Kessans SA; Kilbourne J; Kibler KV; Pantaleo G; Roderiguez ME; Blattman JN; Jacobs BL; Mor TS
Virology; 2017 Jul; 507():242-256. PubMed ID: 28458036
[TBL] [Abstract][Full Text] [Related]
17. Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.
Cox JH; Ferrari MG; Earl P; Lane JR; Jagodzinski LL; Polonis VR; Kuta EG; Boyer JD; Ratto-Kim S; Eller LA; Pham DT; Hart L; Montefiori D; Ferrari G; Parrish S; Weiner DB; Moss B; Kim JH; Birx D; VanCott TC
Vaccine; 2012 Feb; 30(10):1830-40. PubMed ID: 22234262
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus.
Khattar SK; Palaniyandi S; Samal S; LaBranche CC; Montefiori DC; Zhu X; Samal SK
Hum Vaccin Immunother; 2015; 11(2):504-15. PubMed ID: 25695657
[TBL] [Abstract][Full Text] [Related]
19. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
Churchyard GJ; Morgan C; Adams E; Hural J; Graham BS; Moodie Z; Grove D; Gray G; Bekker LG; McElrath MJ; Tomaras GD; Goepfert P; Kalams S; Baden LR; Lally M; Dolin R; Blattner W; Kalichman A; Figueroa JP; Pape J; Schechter M; Defawe O; De Rosa SC; Montefiori DC; Nabel GJ; Corey L; Keefer MC;
PLoS One; 2011; 6(8):e21225. PubMed ID: 21857901
[TBL] [Abstract][Full Text] [Related]
20. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]